Novartis Is Dialing Out Of Its Listed Indian Arm – The Possibilities

Novartis initiates strategic review of listed Indian entity including taking a call on its 70.68% shareholding. Industry pundits point to potential suitors and options that may be at play.

Novartis reviews options for listed Indian arm • Source: Shutterstock

Way back in March 1996, Swiss pharmaceutical companies Ciba-Geigy and Sandoz. decided to merge and form what was then the world’s biggest life sciences combine christened Novartis.

Key Takeaways
  • Novartis AG initiates strategic review of listed entity in India

The India merger of local arms Hindustan Ciba-Geigy Limited and Sandoz (India) Limited came a year on, post various approvals...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

Multiple Factors Driving Japan’s Pioneering Angiosarcoma Pipeline

 
• By 

Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.

Bristol’s Q2 Earnings Homerun Overshadowed By Clinical Trial Review Curveball

 
• By 

Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

 
• By 

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.